Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer

Fig. 2

HER3 is necessary for AXL to mediate cetuximab resistance. A HN30-AXL and PCI37A-AXL cells were plated and treated with 30 nM of HER3 siRNA (siHER3) or 30 nM non-target siRNA (siNT). The next day, cells were treated with 100 nM of IgG or 100 nM cetuximab (Ctx) for 72 h. Cell proliferation was measured after drug treatment by CCK8 assay. Mean values, SEs, and statistical analyses are representative of three independent experiments. N = 5–10, **P < 0.01. Whole cell lysates were collected 24 h after treatment, fractionated by SDS-PAGE and immunoblotted for the indicated proteins. GAPDH was used as a loading control. B UMSCC1 and UMSCC6 HNSCC cells were plated and treated with 30 nM of siAXL or 30 nM siNT. The next day, cells were treated with 100 nM of IgG or 100 nM Ctx for 72 h. Cell viability was measured after drug treatment by crystal violet assay. Mean values, SEs, and statistical analyses are representative of three independent experiments. N = 3, **P < 0.01. Whole cell lysates were collected at 24 h after treatment, fractionated by SDS-PAGE, and immunoblotted for the indicated proteins. GAPDH was used as a loading control

Back to article page